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Abstract
Surgical resection and imaging guided treatments 
play a crucial role in the management of hepatocel-
lular carcinoma (HCC). Although the primary end point 
of treatment of HCC is survival, radiological response 
could be a surrogate end point of survival, and has a 
key role in HCC decision-making process. However, 
radiological assessment of HCC treatment efficacy is 
often controversial. There are few doubts on the evalu-
ation of surgical resection; in fact, all known tumor 
sites should be removed. However, an unenhancing 
partial linear peripheral halo, in most cases, surround-
ing a fluid collection reducing in size during follow-up 
is demonstrated in successfully resected tumor with 
bipolar radiofrequency electrosurgical device. Efficacy 
assessment of locoregional therapies is more contro-
versial and differs between percutaneous ablation (e.g. , 
radiofrequency ablation and percutaneous ethanol 
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injection) and transarterial treatments (e.g. , conven-
tional transarterial chemoembolization, transarterial 
chemoembolization with drug eluting beads and radio-
embolization). Finally, a different approach should be 
used for new systemic agent that, though not reducing 
tumor mass, could have a benefit on survival by delay-
ing tumor progression and death. The purpose of this 
brief article is to review HCC imaging appearance after 
treatment.
© 2013 Baishideng. All rights reserved.
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Core tip: Surgical resection and imaging guided treat-
ments play a crucial role in the management of hepa-
tocellular carcinoma (HCC). Moreover, recent studies 
have underlined the potential of antiangiogenetic treat-
ment in patients with untreatable, unresectable HCCs. 
The purpose of this article is to review HCC imaging 
appearance after treatment.
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Hepatocellular carcinoma (HCC) is the most common 
primary malignant liver tumor. Surgical resection and liver 
transplantation are the only potentially curative options, 
but they are contraindicated in most patients[1,2]. Other 
available imaging guided tools for the treatment of  HCC 
are radiofrequency ablation, ethanol injection, transarteri-
al chemoembolization and radioembolization. These op-
tions are not curative, they do increase survival and they 
are used to downstage patients in order to be suitable 
to liver transplantation. Moreover, recent studies have 
underlined the potential of  antiangiogenetic treatment in 
patients with untreatable, unresectable HCCs[3,4]. Imaging 
follow-up plays a crucial role in evaluating treatment ef-
fectiveness and therefore in taking important decisions in 
the management of  these patients. In this article, we will 
review the imaging appearance of  HCC after treatment.
EVALUATION OF TUMOR RESPONSE 
WITH IMAGING 
Currently there are no recommendations regarding the 
timing for radiological follow-up to assess treatment re-
sponse and schedules shaped by randomized controlled 
trials (RCTs) are very heterogeneous[5]. At our institution, 
treatment efficacy is evaluated using dynamic computed 
tomography (CT) or magnetic resonance (MR) exami-
nations at one, 3 and 6 mo after treatment, and every 6 
mo afterwards. The first evaluation performed at one 
month is crucial to assess response to treatment and the 
presence of  postprocedural complications. Subsequent 
follow-up is essential to detect tumor recurrence or the 
occurrence of  new foci of  HCC. 
Liver resection with radiofrequency tissue coagulation 
device
Radiofrequency (RF)-assisted liver resection technique 
uses RF energy to obtain parenchymal dissection by cre-
ating a zone of  coagulative necrosis along the transection 
plane[6]. This reduces the risk of  intraoperative blood 
loss when compared with conventional liver resection[6]. 
Liver resection is indicated in patients with preserved 
liver function and single HCC, ideally in a subcapsular 
location[1]. Resected area must be larger than the original 
tumor and with a margin greater than 5 mm[7]. On CT, 
resection margin typically appears as an hypoattenuat-
ing, non enhancing halo[8,9] (Figure 1). On MR, resection 
margin is commonly hyperintense on T2-weighted im-
ages and hypointense on T1-weighted images and does 
not enhance after gadolinium injection[8,9]. Residual viable 
tissue, when present, is usually located along the resec-
tion site and shows arterial enhancement and venous 
wash-out[8,9]. A fluid collection within the resected area is 
commonly found at initial follow-up and disappears with 
time[9]. Uncommon complications include biloma, hepatic 
abscess, pleural effusion and adjacent organ injury (i.e., 
small bowel perforation). 
Percutaneous ablation
Percutaneous ablation induces coagulative necrosis by 
modifying tumor temperature using RF, microwave, laser, 
cryotherapy or by direct intratumoral injection of  chemi-
cal substances (ethanol or acetic acid). This procedure is 
recommended for patients with preserved liver function 
and a maximum of  3 small (≤ 3 cm) HCCs[1].
RF ablation: RF ablation (RFA) is the most widely used 
ablation therapy. RFA ablation consists of  placing a nee-
dle electrode directly into the tumor, by US or CT guid-
ance, and heating tissue to temperatures exceeding 60 ℃[10] 
to obtain the coagulative necrosis of  the tumor. Similarly 
to resected area, ablation zone should be 5-10 mm larger 
in comparison to the preexisting tumor[11]. Due to a coag-
ulative necrosis and hemorrhagic products, treated HCC 
is typically hypoattenuating or heterogeneously hyperat-
tenuating on unenhanced CT. Contrast enhanced images 
help differentiate viable from necrotic tumor. In general, 
successfully treated HCC shows absence of  arterial en-
hancement (Figure 2), whereas any nodular arterially 
enhancing area within or along the margin of  the ablated 
zone is suspicious of  viable tumor[10]. Moreover, patients 
treated with RFA are considered at higher risk in com-
parison to the general cirrhotic population for the occur-
rence of  new foci of  HCC (Figure 3). However, absence 
of  arterial enhancement at CT does not imperatively cor-
respond to absence of  viable tissue[11]. Lu et al[11] reported 
100% specificity and 36% sensitivity of  CT for the depic-
tion of  residual or recurrent tumor. In their study, only 
4/11 (37%) HCCs with positive histological findings were 
detected at CT[11]. These observations are in agreement 
with a study by Dromain et al[12] who also found that MRI 
allowed earlier detection of  residual tumor than does CT. 
At MR, successfully treated HCC shows T2-hypointensity 
and strong T1-hyperintensity[12]. The inclusion of  sub-
traction images in the MR protocol increases detection 
of  residual arterial enhancement in those cases of  HCC 
with spontaneuous T1 hyperintensity[13]. At initial follow-
up studies, treated HCC may show a thin and peripheral 
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Figure 1 Successful hepatocellular carcinoma 
resection with radiofrequency tissue coagulation 
device. A: Pretreatment arterial phase T1-weighted 
gradient-echo magnetic resonance shows hypervas-
cular hepatocellular carcinoma (HCC) (arrow); B: On 
arterial phase computed tomography obtained 4 mo 
after treatment no hypervascular focus is evident (ar-
row). Note that resected area is larger to preexisting 
HCC.
A B
arterially enhancing rim, due to inflammatory reaction to 
thermal necrosis[14,15]. This rim sometimes shows hypoat-
tenuation on unenhanced CT and mild hypertintensity on 
T2-weighted images. More rarely, needle electrode placing 
can cause formation of  arterio-venous shunts[14,15]. These 
shunts can be easily diagnosed on the basis of  wedge-
shaped morphology, peripheral location and lack of  wash 
out on portal venous phase (Figure 4). However, if  the 
arterially enhancing zone is small and nodular, a correct 
characterization may be difficult and a 3-6 mo follow-up 
is recommended[16]. Size increase of  arterially enhanc-
ing area, or the appearance of  wash-out may suggest 
presence of  viable tumor. Other complications include 
biloma, hepatic abscess, portal vein thrombosis (Figure 5), 
arterial pseudoaneurysm (Figure 6), tumor seeding (Figure 
7) and adjacent organ injury[17]. 
Percutaneous ethanol injection: Percutaneous ethanol 
injection (PEI) consists of  percutaneous ethanol instilla-
tion into the HCC by sonographic or CT guidance. It is 
a well-tolerated, inexpensive procedure with few adverse 
effects. This alternative procedure may be performed in 
those patients with small HCCs, in whom RFA is not 
suitable to be performed due to tumor location[18]. In 
fact, some tumors are located at risky sites (defined as 
less than 5 mm from a large vessel or an extrahepatic 
organ, near gallbladder, or in subphrenic locations) and 
RFA treatment can cause severe complications. In addi-
tion, in tumors larger than 2 cm in size, initial RF may 
leave a tiny nest of  viable tissue that will easily be ablated 
by ethanol with a relevant saving of  resources. However, 
several studies demonstrated that PEI provides a lower 
rate of  complete necrosis in comparison to RFA[19-21]. CT 
and MR post-treatment imaging features are similar to 
those obtained after RFA[22] (Figure 8). 
Transarterial chemoembolization
Transarterial chemoembolization (TACE) consists of  
transarterial administration of  a mixture of  chemotherapy 
(Doxorubicin or Cisplatin in most cases) and iodized 
oil (Lipiodol, Guerbert, France), followed by emboliz-
ing particles[23]. Since HCC receives blood supply almost 
completely from the hepatic artery (as opposed to nor-
mal liver), these agents accumulate preferentially into 
HCC lesions. Iodized oil acts as chemotherapy carrier, 
while particles occlude tumor feeding arteries. Therefore, 
TACE combines delivery of  high dose chemotherapy to 
the tumor with embolization of  its feeding arteries. The 
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Figure 2  Complete necrosis after radiofrequency ablation for hepatocel-
lular carcinoma. A: Pretreatment arterial phase computed tomography (CT) 
shows hypervascular hepatocellular carcinoma (arrow); B: Arterial phase CT 
obtained 1 mo after treatment shows ablated area (arrow). Absence of arterial 




Figure 3  Hepatocellular carcinoma after multiple radiofrequency abla-
tions. A: Arterial phase computed tomography (CT) obtained 8 mo after radio-
frequency ablation shows two new enhancing hepatocellular carcinoma (HCC) 
nodules located anteriorly (dotted arrow) and posteriorly (short arrow) to ablated 
HCC (long arrow). These findings suggest occurrence of new HCC nodules; B: 
Arterial phase CT obtained 2 mo after additional radiofrequency (RF) ablation 
shows that HCC nodule located anteriorly (dotted arrow) has been replaced by 
a hypoattenuating, non enhancing area (arrow) that is larger than preexisting 
tumor. These findings suggest complete necrosis. Posteriorly located HCC (short 
arrow) increased in size; C: Arterial phase CT obtained 2 mo after posterior. 
HCC had been replaced by a hypoattenuating, nonenhancing ablation area 
as a result of additional RF ablation. This example shows that RF ablation is a 
repeatable procedure. 
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assumption that tumor portion that retains iodized oil is 
necrotic, while enhancing foci represent viable tissue[10]. 
However, it is sometimes difficult to detect viable tissue, 
because beam hardening artefacts produced by iodized oil 
can impair evaluation of  arterial enhancement[10] (Figure 
9A and B). Kim et al[25] reported that use of  unenhanced 
phase in conjunction with biphasic CT could improve 
the detection of  additional foci of  viable tumor. Accord-
ing to this study, an HCC treated with TACE could be 
considered viable if  it showed hyperattenuation or isoat-
tenuating on hepatic arterial phase and hypoattenuation 
on unenhanced and portal venous phases. MRI is known 
to be superior to CT for the evaluation of  HCC after per-
forming TACE[26] (Figure 9C and D). Completely necrotic 
HCC usually shows variable signal intensity on unen-
hanced T1-weighted images and T2-weighted images and 
lack of  enhancement after gadolinium injection[27]. MR 
accuracy is however relatively low. Hunt et al[28] reported 
an overall accuracy rate of  55%, with 43% sensitivity and 
75% specificity. Treated HCC sometimes shows a thin and 
peripheral pseudocapsule that enhances on hepatic arte-
major indications for TACE are multiple HCCs without 
vascular invasion or extrahepatic spread and HCCs for 
which percutaneous ablation is precluded by position (e.g., 
pericholecistic, subphrenic, etc.) or size[1]. TACE is also 
indicated in those patients in whom previous procedures 
have failed[1,24]. At initial post-treatment examinations, 
treated HCC usually presents the same size of  the preex-
isting tumor. The evaluation of  CT images is based on the 
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Figure 5  Portal vein thrombosis after radiofrequency ablation for hepato-
cellular carcinoma. Arterial phase computed tomography obtained 1 mo after 
radiofrequency ablation shows a non enhancing thrombus in intrahepatic portal 
vein (white arrow), in proximity of ablated area (black arrow). 
A B
Figure 6  Arterial pseudoaneurysm after radiofrequency ablation for hepa-
tocellular carcinoma. Post-treatment arterial phase (A) computed tomography 
(CT) shows a round enhancing area (long arrow) anterior to ablated zone (dot-
ted arrow) with persistent enhancement on portal venous phase (B) CT. Round 
shape, isoattenuation to aorta and absence of wash-out suggest diagnosis of 
iatrogenic pseudoaneurysm. Note probe track (short arrow on A and B).
Figure 7  Tumor seeding after radiofrequency ablation for hepatocellular 
carcinoma. Arterial phase computed tomography shows heterogeneously 
enhancing hepatocellular carcinoma tissue (arrow) invading muscles of the 
anterior abdominal wall along needle tract.
A
B
Figure 4  Perfusion alteration after radiofrequency ablation for hepatocel-
lular carcinoma. A: Arterial phase computed tomography (CT) obtained 1 mo 
after treatment shows ablated zone (dotted arrow) and a semilunar enhancing 
area (solid arrow) medial and anterior to ablated zone; B: Delayed phase CT 
shows persistent enhancement of the semilunar area (solid arrow), suggesting 
that the arterial enhancement is due to perfusion alteration rather than residual 
tumor.
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rial and delayed phases. Moreover, iodized oil can some-
times injury small hepatic arteries and cause formation 
of  arterio-portal shunts. Absence of  wash-out is crucial 
to differentiate these pseudolesions from residual viable 
tumor. Other complications include hepatic artery injuries 
(dissection or thrombosis), biloma, hepatic abscess and 
embolization of  non target vessels[29]. Non target vessels 
include arteries that arise from the hepatic circulation 
(gastroduodenal, right gastric, accessory left gastric, cystic 
arteries)[30]. Embolization of  these vessels results in gas-
trointestinal ulcers, skin ulcerations, and, rarely, ischemic 
cholecystitis[29,30]. Furthermore, although the purpose of  
TACE is to obtain a selective intratumoral delivery of  
chemioterapy, several studies demonstrated that many pa-
tients may have higher plasma levels of  chemotherapeutic 
agents with systemic toxic effects[31]. Therefore, alternative 
techniques that increase the precision of  drug delivery are 
required. TACE with drug eluting beads (DEB) is recently 
emerging as an alternative option to conventional TACE. 
TACE with DEB consists of  transarterial injection of  
microspheres that sequester chemotherapy immediately 
before administration and release it into the tumor in a 
sustained and controlled manner[18]. In addition, absence 
of  iodized oil does not mask arterial enhancement[32] 
421 August 27, 2013|Volume 5|Issue 8|WJH|www.wjgnet.com
Figure 8  Incomplete hepatocellular carcinoma 
necrosis after percutaneous ethanol injec-
tion. Arterial (A) and portal venous (B) computed 
tomography obtained 1 mo after treatment shows 
that approximately 10%-20% of the tumor, located 
in the dorsal and lateral portion of the treated, hy-
poattenuating area, is still viable as demonstrated 
by the presence of enhancement in arterial phase 
and hypoattenuation (“washout”) on portal venous 
phase (dotted arrow on A and B). The majority of 
tumor (solid arrow) does not show enhancement as 




Figure 9  Incomplete hepatocellular carcinoma necrosis after transarte-
rial chemoembolization. Arterial (A) and portal venous (B) phase computed 
tomography (CT) obtained 1 mo after transarterial chemoembolization (TACE) 
shows that hepatocellular carcinoma (HCC) is entirely replaced by Lipiodol ac-
cumulation (arrow). No evidence of residual tumor was found. Arterial (C) and 
portal venous (D) phase T1-weighted gradient-echo magnetic resonance (MR) 
obtained 1 wk after CT shows residual viable tumor (arrow) in the posterolateral 
portion of the tumor. This case shows higher accuracy of MR in comparison to 
CT in assessing HCC response after TACE. 
A
B
Figure 10  Complete hepatocellular carcinoma necrosis after transarterial 
chemoembolization with drug-eluting beads. A: Pretreatment arterial phase 
computed tomography (CT) shows a hypervascular hepatocellular carcinoma 
(HCC) (arrow); B: Arterial phase CT obtained 3 mo after transarterial chemoem-
bolization shows a hypoattenuating, non enhancing nodule (arrow). Absence of 
arterial enhancement suggests complete HCC necrosis. 
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(Figure 10), allowing easier assessment of  residual, viable 
tumor in comparison to traditional TACE performed with 
iodized oil. 
Radioembolization
An alternative technique to treat advanced HCC is radio-
embolization. It consists of  transarterial administration 
of  yttrium-90 microspheres that are preferentially depos-
ited within hypervascular tumors and that emit lethal beta 
radiation[18]. This induces tumor coagulative necrosis and 
avascularity. Post-treatment HCC appearance is similar to 
that obtained following RFA and PEI[33].
Targeted therapy
Targeted therapies are a new generation of  anticancer 
drugs designed to interfere with tumor growth and pro-
gression. Sorafenib, a multikinase inhibitor, is the only 
drug that has been demonstrated to significantly improve 
survival in patients with untreatable, unresectable HCCs 
in a large randomized controlled trial[3]. Sorafenib reduces 
tumor vascularization and subsequently induces tumor 
necrosis and hemorrhage[3] (Figure 11). For these rea-
sons, the traditional WHO and RECIST criteria based on 
evaluation of  tumor size may not be ideal to determine 
tumor response. Therefore, different criteria based on 
assessment of  viable and enhancing tumor are needed. 
Modified RECIST (mRECIST) differ from RECIST 
criteria, since they consider only the diameter of  viable 
tumor, defined as the portion of  the tumor that shows 
arterial enhancement and venous wash-out[5,34]. Recent 
studies have reported the potential of  perfusion CT and 
MR[35,36]. However, high CT radiation dose, MR breath-
ing, cardiac motion and high costs limit the use of  these 
techniques[35,37,38].
CONCLUSION
Advances in HCC treatment have led to an increased use 
of  therapeutic tools such as RF and percutaneous abla-
tion, TACE and antiangiogenetic therapy. In this scenario, 
CT and MR play an important role in the assessment of  
response to treatment. Therefore, every radiologist and 
hepatologist should be familiar with the HCC appearance 
after treatment and should be able to distinguish normal 
post-treatment changes from residual or recurrent tumor.
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